Hospital-at-home inpatient care is no worse than its traditional counterpart at facilitating good clinical outcomes for comparable overall costs. In fact “HaH” is sometimes considerably better on both those scores.

New data out of the AATS Annual Meeting identified significant potential for a new treatment strategy. 

Data from BENEFIT-HF, a new randomized study of CVRx's implantable Barostim device, could open up access to many more heart failure patients.